A randomized, placebo-controlled first-in-human study of oral TQS-168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect.
Jonas Hannestad, Steven Smith, Andrew Lam, Janet Hurt, Nicole Harada, Richard Kim, Abhirup Das, Juliana Brunello, Gareth Whitaker, David Chalmers, Faria Senjoti, Wu Lin, James Coghill, Yogesh Bansal, Sharan Sidhu, Vanessa Zann, Enchi Liu
Author Information
Jonas Hannestad: Tranquis Therapeutics, Inc., Palo Alto, California, USA. ORCID
Steven Smith: Tranquis Therapeutics, Inc., Palo Alto, California, USA. ORCID
Andrew Lam: Tranquis Therapeutics, Inc., Palo Alto, California, USA.
Janet Hurt: Tranquis Therapeutics, Inc., Palo Alto, California, USA.
Nicole Harada: Tranquis Therapeutics, Inc., Palo Alto, California, USA.
Richard Kim: Tranquis Therapeutics, Inc., Palo Alto, California, USA.
Abhirup Das: Tranquis Therapeutics, Inc., Palo Alto, California, USA.
Juliana Brunello: Tranquis Therapeutics, Inc., Palo Alto, California, USA. ORCID
TQS-168, a first-in-class small-molecule inducer of peroxisome proliferator-activated receptor gamma coactivator 1-alpha gene expression, is in development for the treatment of amyotrophic lateral sclerosis. A single-ascending-dose (SAD) and multiple-ascending-dose (MAD) study of TQS-168 was carried out in healthy male subjects to investigate safety, tolerability, pharmacokinetics (PK), food effect, and preliminary pharmacodynamic effects (PD). Since solubility enhancement could be beneficial, assessment of three formulations was incorporated into the study using an integrated rapid manufacturing and clinical testing approach. Dosing in the SAD part was initiated with a crystalline methylcellulose (MC) suspension, and then spray-dried dispersion (SDD) and hot-melt extrusion (HME) suspensions were evaluated. The HME and SDD formulations showed two and fourfold higher exposure than the MC suspension, respectively, and the SDD formulation was selected for progression to subsequent SAD and MAD cohorts, in which there was further investigation of the food effect on exposure in addition to assessments of safety, tolerability, PK, and PD. C and AUC plasma exposures of TQS-168 were supra-proportional at higher doses, irrespective of formulation. Median T for TQS-168 occurred between 0.5 and 4.0 h post-dose and occurred later with higher doses. Geometric mean half-lives (T) for TQS-168 were independent of formulation and food, ranging from 3.2 to 10.5 h following single doses and 4.1 to 7.3 h following multiple doses. Food blunted TQS-168 C but had minimal impact on AUC. TQS-168 was considered to be safe and generally well tolerated following single and multiple oral doses. The SDD formulation was selected for future patient studies.
